Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized ...

Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder March 5, 2026 7:30 AM ESTCompany ParticipantsMichael Cola - ...

News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news ...

Helus Pharma HELP shares are down on Thursday following the announcement of topline results from a Phase 2 signal detection study for HLP004, a potential treatment for generalized anxiety disorder ...

The latest announcement is out from Cybin ( (HELP) ).

Helus Pharma (HELP) stock falls as the company posts mid-stage trial data for HLP004, a psychedelic-based therapy for generalized anxiety disorder. Read more here.

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

Cognitive behavioral therapy (CBT) should be considered first-line treatment for generalized anxiety disorder in adults, according to a systematic review and network meta-analysis of 66 randomized ...

CLEVELAND — Researchers narrowed down what appears to be the correct dosage during a first ever rigorous clinical trial examining LSD as a treatment for generalized anxiety disorder, with results ...

Two student clubs at West Career & Technical Academy will host a community arts and crafts event on Sunday aimed at promoting mental wellness and raising awareness of generalized anxiety disorder.

Worry is a protective strategy that can keep us stuck. Explore the hidden emotional costs of worry and discover ...